Kornimate/medical-research-clean huggingface dataset:
ultrasound guided versus landmark guided arterial line placement by emergency medicine interns

Conditions: Vascular Access Complication

Summary: critically ill patients in the emergency department commonly require arterial line placement for continuous direct blood pressure monitoring, frequent arterial blood gas sampling, and frequent blood sampling. trans-radial catheterization has been shown to reduce access site complications and increase patient comfort compared to trans-femoral access. radial artery access on the first attempt is optimal; attempts at reentry delay care and increase the risk of vascular spasm, hematoma, infection, neurovascular injury, and pain. the traditional pulse palpation method of radial artery cannulation can be challenging, especially in patients with weak pulses (i.e. morbidly obese or hypotensive individuals). a review of literature suggests that ultrasound guided trans-radial catheterization compared to standard pulse palpation reduces access time and increases rate of first-entry success when performed by physicians trained in ultrasound. thus, complications ascribed to reentry are prevented and timely care is provided. to the investigator's knowledge, only one other prospective study has been conducted to assess the utility of ultrasound guided radial artery cannulation in the emergency department. due to the paucity of literature to support the use of ultrasound guided trans-radial catheterization in critically ill patients, the study will aim to provide further data on the topic. both techniques are considered standard of care.

patients presenting to the emergency department 18 years old or greater, who do not belong to a vulnerable group, requiring arterial line placement will be included in this trial. the investigators will randomize each patient into lm vs us. data collected will include number of attempts, success rate, and time for procedure to be completed. pgy-1 residents will perform the arterial line placement.

Eligibility criteria:
inclusion criteria: * patients requiring arterial line placement. exclusion criteria: * adults unable to consent * members of vulnerable populations
incidence and risk factors for delirium in severely injured patients

Conditions: Delirium; Trauma; Intensive Care Unit Syndrome

Summary: delirium is very common in intensive care unit (icu) patients and leads to poor outcomes. there is little information on delirium in injured patients however. this study determined the incidence and risk factors for delirium in severely injured patients.

this study was a prospective cohort study that reviewed the medical records of 179 trauma patients who were admitted to asan medical center from january 01, 2013 to december 31, 2014. the investigators included all patients who had an injury severity score (iss) of more than 15 and excluded patients younger than 15 years old. this study was approved by the asan medical center institutional review board (2014-0344). patient delirium was checked using the confusion assessment method in intensive care unit (cam-icu) three times every day. the cam-icu includes four features that assess acute changes in or the fluctuating course of mental status, inattention, altered level of consciousness, and disorganized thinking. if a patient has a richmond agitation sedation scale (rass) score of -3 or more with acute changes in mental status, inattention, and disorganized thinking or altered level of consciousness, a diagnosis of delirium can be made. the investigators considered patients to be delirious when cam-icu was positive for more than 24 h. the investigators reviewed clinical information for the study patients including age, sex, and underlying disease. trauma factors reviewed were cause of trauma, iss, glasgow coma scale (gcs) score, shock, initial lactate level, massive transfusion within 24 h, cardiopulmonary resuscitation rescue, and time taken to the hospital after trauma. factors related to treatment included use of restraints, mechanical ventilation, and surgery. clinical outcomes included mortality, icu stay, mechanical ventilation duration, and hospital stay. statistical analysis were done using both univariate (chi-square test and t-test) and multivariate (logistic regression) procedures. results are reported as mean ± standard deviation. significance set at a p value of less than .05. for the multivariable logistic regression, the primary outcome variable of interest was the development of delirium after trauma that was classified as either present or absent. variables were entered for analysis based on the strength of their univariate association with the presence/absence of delirium.

Eligibility criteria:
inclusion criteria: * trauma patients with injury severity score (iss) more than 15 exclusion criteria: * age under 15

Keywords: delirium trauma injury restraints
pomegranate extract supplementation in colorectal cancer patients

Conditions: Colorectal Cancer

Summary: the most relevant pomegranate phenolics (ellagitannins and ellagic acid) are extensively metabolized by the human gut microbiota to yield a number of metabolites called urolithins (mainly uro-a). urolithins have been reported to regulate in vivo the expression of genes involved in inflammation and cancer. our hypothesis is that urolithins can be detected in the human colon mucosa where these metabolites can exert anti-inflammatory and anti-cancer activities. after colonoscopy and diagnosis, colorectal cancer patients will consume capsules containing three different pomegranate extract formulations until surgery. the aims of this trial are: * to evaluate the disposition of pomegranate phenolics and urolithins in tumoral and normal colon tissues. * to evaluate gene expression profiling and protein markers in tumoral and normal colon tissues from these patients. * to compare different pomegranate extract formulations on the above.


Eligibility criteria:
inclusion criteria: * colorectal cancer diagnosis. * surgery required. * who status: between 0 and 2. * hemoglobin \>10 g/dl * alt \>2.5-fold above the normal value. * serum bilirubin \>1.5-fold above the normal value. * creatinine \<140 micromol/l exclusion criteria: * patients who do not satisfy inclusion criteria and, * active pectic ulcer. * pregnancy or breastfeeding. * alcoholism. * chemotherapy or radiotherapy a month prior to recruitment. * treatment with steroids or other anti-inflammatory drugs a week prior to recruitment.

Keywords: pomegranate urolithins colorectal cancer colon cancer metabolite gene expression microrna nutraceutical food supplement polyphenol gut microbiota
brief motivational enhancement therapy for concurrent disorders

Conditions: Psychosis; Substance Use

Summary: the investigators are proposing a project that will examine the effectiveness of brief motivational enhancement therapy in a population with concurrent psychotic disorders and substance use disorders. this study will represent an emerging line of inquiry, as best practice interventions with this concurrent disordered (cd) populations are yet to be established.

motivational enhancement therapy (met) is grounded in research that explores the process of change. the met approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. the met approach aims to invoke rapid and internally motivated change. the two met sessions adapted from sampl and kadden (2001) are prepared as two individual sessions to reflect the original design of met, allowing for client's to be met at their respective stage of change. further, individual sessions allow the treatment to be tailored to client's individual reasons for change and personal coping strategies. the use of the personalized feedback report (pfr) further encourages treatment around client's personal concerns and goals (ramchand et al., 2011; see appendix 1 for further detail). in the first treatment session, the therapist provides feedback from the initial cd consultation, using the pfr to stimulate discussion about personal substance use and reasons for change. rapport building is also a key element to the first session, during which a strong therapeutic alliance is initiated. the second session is aimed at strengthening the commitment to change, exploring goal setting, and preparation for group. the centre for addiction and mental health (camh) schizophrenia division introduced a cd service in 2009. since the time of its inception, more than 200 consultations have been conducted. of those consultations, more than 80%recommended attending cd groups offered with the schizophrenia program. however, less than 10% have followed those recommendations and attended the cd group. based on what is known about challenges surrounding engagement of cd clients in recommended treatments coupled with guidelines for evidence-based treatment with this population (ledgerwood et al., 2008; tsuang et al., 2006; roncero et al., 2011), the purpose of the current study is to explore the ability of met to increase engagement in cd interventions for clients diagnosed with psychotic and substance use disorders.

Eligibility criteria:
inclusion criteria: * between the ages of 16-65 * dsm-iv diagnoses of a psychotic disorder and a substance use disorder (tobacco, alcohol and/or drug) * fluent english speaker * capable of giving written informed consent exclusion criteria: * any medical or neuropsychiatric condition, illness or disorder (e.g. unstable angina, severe dementia) that could compromise attendance to outpatient appointments. * inability to provide informed consent.

Keywords: psychosis substance use motivational enhancement therapy
a study of ixekizumab in participants with active psoriatic arthritis

Conditions: Psoriasis, Arthritic

Summary: this study will assess the safety and efficacy of ixekizumab (ly2439821) compared to placebo in participants with active psoriatic arthritis.


Eligibility criteria:
inclusion criteria: * presents with established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets classification for psoriatic arthritis (caspar) criteria * active psoriatic arthritis (psa) defined as the presence of at least 3 tender and at least 3 swollen joints * presence of active psoriatic skin lesion or a personal history of plaque psoriasis (ps) * men must agree to use a reliable method of birth control or remain abstinent during the study * women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment exclusion criteria: * current or prior use of biologic agents for treatment of ps or psa * inadequate response to greater than or equal to 4 conventional disease-modifying antirheumatic drugs (dmards) * current use of more than one conventional dmard * evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than psa * have participated in any study with interleukin 17 (il-17) antagonists, including ixekizumab * serious disorder or illness other than psoriatic arthritis * serious infection within the last 3 months * breastfeeding or nursing (lactating) women
changeovers of norepinephrine in intensive care

Conditions: Shock; Intensive Care

Summary: chic study's purpose is to compare the efficiency, in terms of blood pressure stability, of three changeovers of norepinephrine used routinely in icu. the three techniques are: * quick change * double pumping * smart infusion pumps

the drugs used in intensive care units are numerous and their administration is based on a strong expertise in this context of urgency and complexity. nurses role is not only to carry out preparation of a treatment but to implement a complex treatment that requires a risk management approach surpassing the simple task to which the decree of professional acts refers to. in this context, the administration of catecholamines, widely used in intensive care medicine in the treatment of shock, appears to be a sensitive issue to study. these vasoactive drugs have a short half-life and a narrow therapeutic index. administration should be careful ensuring both efficiency and prevention of complications such as hemodynamic instability or arrhythmias. administration of these therapeutic must be strictly continuous, that is to say delivered using electric syringe pumps. syringe replacements appear as critical moments because of the risk of flow change or brief interruption of the infusion. there are three main types of syringes relay techniques, but to date, no study has compared these techniques with each other. there is thus no recommendation based on objective datas to guide clinical nursing practice. this study aims to provide evidence in order to secure the administration of catecholamines. it may also use as a reference for evaluation of new features that allow automation relays with called "smart pumps" and for which no study has demonstrated the added value in terms of security. no progress will be possible in securing the administration of drugs with a short half-life, narrow therapeutic index and significant side effects without a deep reflection of the conditions of their infusion. the choice of materials used and the development of care procedures must be based on reliable and timely recommendations. patients expect safer care. nurses must be able to have references enabling them to guide their practice to the benefit of patients.

Eligibility criteria:
inclusion criteria: * admission in intensive care unit * norepinephrine perfusion started for less than three hours in icu * invasive monitoring of blood pressure exclusion criteria: * age under 18 * pregnant and breastfeeding women * previous participation in the trial * no registration in any health care system * patient protected by law * patient study refusal * active therapeutic limitation decision

Keywords: norepinephrine intensive care changeovers smart pumps quick change double pumping shock
to assess the safety and tolerability of incb000928 in participants with myelodysplastic syndromes or multiple myeloma

Conditions: Myelodysplastic Syndromes; Multiple Myeloma; Anemia

Summary: this phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, pk, pd, and efficacy of incb000928 administered as monotherapy in participants with mds or mm who are transfusion-dependent or present with symptomatic anemia.


Eligibility criteria:
inclusion criteria: * agreement to avoid pregnancy or fathering children. * participants who are transfusion-dependent or present with symptomatic anemia for mds participants: * ineligible to receive or have not responded to available therapies for anemia such as esas or lenalidomide. * not requiring cytoreductive therapy other than hydroxyurea. * bm and peripheral blood myeloblast count \< 10%. * histologically confirmed diagnosis of the mds, cmml and unclassifiable mds/mpn overlap syndromes. for mm participants: * histologically confirmed diagnosis of mm. * after failure of available standard treatments such as alkylating agents, glucocorticoids, immunomodulatory drugs (lenalidomide,pomalidomide, or thalidomide), proteasome inhibitors (bortezomib or carfilzomib), and daratumumab. exclusion criteria: * any prior allogeneic stem cell transplantation or a candidate for such transplantation. * any major surgery within 28 days before the first dose of study drug. * any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, or antibody or hypomethylating agent to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug. * undergoing treatment with another investigational medication or having been treated with an investigational medication within 28 days before the first dose of study drug. -undergoing treatment with esas, granulocyte colony-stimulating factor or granulocyte/macrophage colony-stimulating factor, romiplostin, or eltrombopag at any time within 28 days before the first dose of study drug. * undergoing treatment with a strong or potent inhibitor or inducer of cyp3a4/5 within 28 days or 5 half-lives (whichever is longer) before the first dose of study drug or expected to receive such treatment during the study. * history of clinically significant or uncontrolled cardiac disease. * history or presence of an abnormal ecg that, in the investigator's opinion, is clinically meaningful. * presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment. * diagnosis of chronic liver disease.

Keywords: myelodysplastic syndromes multiple myeloma anemia limber
study of dc-cik to treat colorectal cancer

Conditions: Colorectal Cancer

Summary: the purpose of this study is to evaluate the efficacy of dendritic and cytokine-induced killer cells (dc-cik) for colorectal cancer (crc).

60 patients with stage ⅲ crc, who had received neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to nccn guidelines, and got complete response (cr), will be randomly divided into group a (receive dc-cik treatment) or group b (just regularly follow up), and the randomize ratio will be 1:1. patients in group a will receive 2-3 cycles of dc-cik cells treatment (every 4 weeks). patients in group b will have no anti-tumor therapy.

Eligibility criteria:
inclusion criteria: 1. male or female patients ≥ 18 years of age; 2. crc with histological diagnose, and had received neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy and got complete response (cr) with imaging; 3. patients who have a life expectancy of at least 3 months; 4. eastern cooperative oncology group (ecog) performance status was 0 - 1; 5. the bone marrow functioned normally (wbc \> 4.0×109/l, hb \> 120 g/l, plt \> 100×109/l); 6. the ecg results were normal, and the liver and kidney were functional. exclusion criteria: 1. patients who had distant metastases; 2. patients with uncontrolled infection; underlying disease that was severe or life-threatening; 3. patients who were pregnant or lactating; 4. ecog perform status ≥ 2; 5. patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment.

Keywords: colorectal cancer dc-cik crc
a novel fully integrated mobile management solution using cell phone technology for heart failure

Conditions: Heart Failure

Summary: the purpose of this research study is to learn about the use of a cell phone for monitoring patients with heart failure. participants will be asked questions about their heart failure daily and participants will need to answer them. the investigator will try to assess if the questions are easily understood by the participants. the investigator will also assess if the phone-based system for monitoring is easy to use by the participants. the investigator will also assess if the daily questions and interactions increase the self-efficacy, knowledge, and quality of life of participants related to their heart failure.


Eligibility criteria:
inclusion criteria: * have a diagnosis of heart failure * have an anticipated survival ≥ 6 months * receive care at the university of miami or jackson healthcare system * 18 years or older * able to communicate in english and/or spanish * able to operate a cell phone, read, understand, and respond to the questions on the cell phone, and are able to use the weight scale. exclusion criteria: * previous history of unstable coronary syndromes * history of end-stage heart failure or heart transplantation

Keywords: mobile phone self-efficacy quality of life knowledge feasibility
surveillance for new lung primaries

Conditions: Lung Cancer

Summary: the primary goal of this study is to determine the prevalence of tracheobronchial carcinomas in patients with a history of squamous cell cancer of the aerodigestive tract who have been treated with a curative intent and remain disease free. detection of pre-invasive and invasive lesions (moderate to severe dysplasia, cis) with fluorescence bronchoscopic surveillance may help to define the natural history of these lesions and allow earlier intervention should they progress to invasive lesions.


Eligibility criteria:
inclusion criteria: * history squamous cell nsclc who have undergone complete resection or definitive chemotherapy exclusion criteria: * history of an aerodigestive tract carcinoma of non-squamous histology * patients who have stage iiia, iiib or iv squamous cell lung cancer that have undergone resection or chemotherapy within three years * patients who have stage i or ii squamous cell lung cancer that have undergone resection or chemotherapy within one year * patients who have received external beam radiation therapy for treatment of a squamous cell cancer of the lung
positive psychological interventions for patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study aims to determine the effectiveness of positive psychological interventions on the quality of life and well-being levels of patients with multiple sclerosis.two groups will be selected as intervention and control groups. an intervention method consisting of three good things in life and gratitude activities, each lasting two weeks, was determined for the intervention group. an activity was planned for control group participants to write their daily routines.

people with multiple sclerosis (ms) face numerous physical and mental symptoms as well as emotional and social challenges. the fact that the disease usually occurs in young adulthood, when individuals are most productive, causes disability, its unpredictable and variable nature, and the lack of a known treatment make it difficult to live with ms and accept the disease. the physical, cognitive, behavioral and social changes that occur with the disease affect daily life activities, well-being. and greatly affects the quality of life. there are various interventions developed to improve the adaptation processes of individuals diagnosed with a chronic disease such as ms, to prevent and reduce psychiatric symptoms, and to increase quality of life and well-being. one of the intervention approaches is positive psychological interventions from the field of positive psychology. positive psychological interventions are a psychosocial intervention method based on the systematic completion of certain activities aimed at increasing positive emotions, thoughts and behaviors. since the interventions focus on strengthening positive mental states rather than reducing psychological symptoms, they also have an advantage over traditional interventions in that they can be applied to both sick and non-patients. however, it appears that positive psychological intervention studies have just begun to be implemented in patients with ms. in our country, no study has been found using positive psychological intervention in ms patients. this study aims to determine the effectiveness of positive psychological interventions on the quality of life and well-being levels of patients with multiple sclerosis.

Eligibility criteria:
inclusion criteria: * diagnosis of ms by a neurologist according to mcdonald criteria * having at least 1 year of ms history * expanded disability status scale (edss) score measured by the neurology clinic is \<3.5 * being between the ages of 18-65 being literate * ability to communicate in turkish * volunteering to participate in the study exclusion criteria: * having an ms attack and using corticosteroid medication for the last 3 months * a score of 21 or less on the montreal cognitive assessment (moca) test * having a mental or organic disability in communicating * being diagnosed with any chronic disease other than ms * using psychotropic medication or continuing psychotherapy * not having or being able to obtain a phone that can connect to the internet

Keywords: multiple sclerosis, quality of life, well-being